IP Library Patent Application 12748733
Patent Application
App. No. 12/748,733

Pharmaceutical Composition Containing Botulinum Neurotoxin

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/748,733
Abstract

A composition, medicament or use, comprising or consisting of botulinum toxin type A2 and a surfactant, having one or more or all of the characteristics selected from the group consisting of; (a) a much longer duration of action; (b) a much faster rate of onset of muscular paralysis; (c) a significantly greater intramuscular safety margin; (d) a selective action on inhibition of skeletal muscle contraction; (e) a selective action on inhibition of pain-related (nociceptive) nerve cell function: Wherein each characteristic is determined comparative to the same characteristic effect of botulinum toxin type A1.

Claims (3)

1 - 14 . (canceled)

15 . A method of treatment of a disease, condition, or syndrome selected from the group consisting of: ophtalmological disorders, movement disorders, otorhinolaryngological disorders, gastrointestinal disorders, urogenital disorders, dermatological disorders, pain disorders, inflammatory disorders, secretory disorders, respiratory disorders, hypertrophic disorders, articular disorders, endocrine disorders, autoimmune diseases, proliferative diseases, traumatic injuries and veterinary disorders, said method comprising the step of administering an effective amount of botulinum toxin type A2 to a subject in need thereof.

16 . A method for treatment of cosmetic disorders selected from the group consisting of: skin defects; facial asymmetry; wrinkles selected from glabellar frown lines and facial wrinkles; downturned mouth; and hair loss; said method comprising the administration of an effective dose botulinum toxin type A2 to an area of a subject affected by the cosmetic disorder.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2010
From: IPSEN DEVELOPMENTS LIMITED
To: IPSEN BIOPHARM LIMITED
Reel/Frame 024452/0646 →